Search research articles
Contact Us
Filters
Showing results (141-150 of 255) with videos related to
Page
of 26
Sort By:
Frontiers in Oncology
|
March 16, 2019
Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy
Robert Frank Cornell, Samuel Z Goldhaber, Brian G Engelhardt, et al.
Frontiers in Immunology
|
June 18, 2020
Protection From Influenza by Intramuscular Gene Vector Delivery of a Broadly Neutralizing Nanobody Does Not Depend on Antibody Dependent Cellular Cytotoxicity
Joanne Marie M Del Rosario, Matthew Smith, Kam Zaki, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
October 15, 2013
Geographic distance is not associated with inferior outcome when using long-term transplant clinic strategy
Brittany Knick Ragon, Carey Clifton, Heidi Chen, et al.
Vaccines
|
September 23, 2022
Development of an ELISA-Based Potency Assay for Inactivated Influenza Vaccines Using Cross-Reactive Nanobodies
Chung Y Cheung, Sitara Dubey, Martina Hadrovic, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
July 6, 2016
Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and Rituximab Is Associated with Improved Outcomes Compared with Fludarabine and Busulfan after Allogeneic Stem Cell Transplantation for B Cell Malignancies
Vanessa E Kennedy, Bipin N Savani, John P Greer, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
June 22, 2010
Pretransplantation C-Peptide level predicts early posttransplantation diabetes mellitus and has an impact on survival after allogeneic stem cell transplantation
Michelle L Griffith, Madan H Jagasia, Amanda A Misfeldt, et al.
British Journal of Haematology
|
April 22, 2020
Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents
Robert F Cornell, Samuel Z Goldhaber, Brian G Engelhardt, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
September 3, 2017
Optimizing Antithymocyte Globulin Dosing for Unrelated Donor Allogeneic Hematopoietic Cell Transplantation Based on Recipient Absolute Lymphocyte Count
Vanessa E Kennedy, Heidi Chen, Bipin N Savani, et al.
Acta Oncologica (Stockholm, Sweden)
|
January 17, 2015
Oncologists' weighing of the benefits and side effects of adjuvant systemic therapy: Has it changed over time?
Ellen G Engelhardt, Hanneke C J M de Haes, Cornelis J H van de Velde, et al.
Bone Marrow Transplantation
|
April 5, 2016
How do I manage hyperglycemia/post-transplant diabetes mellitus after allogeneic HSCT
S Fuji, A Rovó, K Ohashi, et al.
Page
of 26
Search research articles
Search
Showing results (141-150 of 255) with videos related to
Sort By:
Page
of 26
Frontiers in Oncology
|
March 16, 2019
Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy
Robert Frank Cornell, Samuel Z Goldhaber, Brian G Engelhardt, et al.
Frontiers in Immunology
|
June 18, 2020
Protection From Influenza by Intramuscular Gene Vector Delivery of a Broadly Neutralizing Nanobody Does Not Depend on Antibody Dependent Cellular Cytotoxicity
Joanne Marie M Del Rosario, Matthew Smith, Kam Zaki, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
October 15, 2013
Geographic distance is not associated with inferior outcome when using long-term transplant clinic strategy
Brittany Knick Ragon, Carey Clifton, Heidi Chen, et al.
Vaccines
|
September 23, 2022
Development of an ELISA-Based Potency Assay for Inactivated Influenza Vaccines Using Cross-Reactive Nanobodies
Chung Y Cheung, Sitara Dubey, Martina Hadrovic, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
July 6, 2016
Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and Rituximab Is Associated with Improved Outcomes Compared with Fludarabine and Busulfan after Allogeneic Stem Cell Transplantation for B Cell Malignancies
Vanessa E Kennedy, Bipin N Savani, John P Greer, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
June 22, 2010
Pretransplantation C-Peptide level predicts early posttransplantation diabetes mellitus and has an impact on survival after allogeneic stem cell transplantation
Michelle L Griffith, Madan H Jagasia, Amanda A Misfeldt, et al.
British Journal of Haematology
|
April 22, 2020
Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents
Robert F Cornell, Samuel Z Goldhaber, Brian G Engelhardt, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
September 3, 2017
Optimizing Antithymocyte Globulin Dosing for Unrelated Donor Allogeneic Hematopoietic Cell Transplantation Based on Recipient Absolute Lymphocyte Count
Vanessa E Kennedy, Heidi Chen, Bipin N Savani, et al.
Acta Oncologica (Stockholm, Sweden)
|
January 17, 2015
Oncologists' weighing of the benefits and side effects of adjuvant systemic therapy: Has it changed over time?
Ellen G Engelhardt, Hanneke C J M de Haes, Cornelis J H van de Velde, et al.
Bone Marrow Transplantation
|
April 5, 2016
How do I manage hyperglycemia/post-transplant diabetes mellitus after allogeneic HSCT
S Fuji, A Rovó, K Ohashi, et al.
Page
of 26